PRISM BioLab206A東証グロース医薬品FY ending Sep 2025, non-consolidated, J-GAAP

PRISM BioLab revenue and profit

It lost about ¥114 for every ¥100 of sales at the operating level. Revenue changed +121.6% from the prior year.

Five-year trend

Revenue¥677.3M
FY ending Sep 2023: ¥112.9M¥112.9MFY ending Sep 2024: ¥305.6M¥305.6MFY ending Sep 2025: ¥677.3M¥677.3MFY23FY24FY25
Operating income-¥774.5M
FY ending Sep 2023: -¥496.9M-¥496.9MFY ending Sep 2024: -¥782.4M-¥782.4MFY ending Sep 2025: -¥774.5M-¥774.5MFY23FY24FY25
Operating margin-114.3%
FY ending Sep 2023: -440.0%-440.0%FY ending Sep 2024: -256.0%-256.0%FY ending Sep 2025: -114.3%-114.3%FY23FY24FY25

What drives ROE

Net margin × asset turnover = ROA; ROA × financial leverage = ROE

ROA-21.9%
2023: -43.5%-43.5%2024: -36.6%-36.6%2025: -21.9%-21.9%232425
PeriodNet marginAsset turnoverROAFinancial leverageROE
2023——×-43.5%—×—
2024——×-36.6%—×—
2025——×-21.9%—×—

Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.

Asset intensity and goodwill

Annual trends in tangible-asset ratios and goodwill balance.

PPE ÷ revenue0.0%
2023: 0.0%0.0%2024: 0.0%0.0%2025: 0.0%0.0%232425
PPE ÷ total assets0.0%
2023: 0.0%0.0%2024: 0.0%0.0%2025: 0.0%0.0%232425

Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition

Income statement (JPY millions)

ItemFY ending Sep 2023FY ending Sep 2024FY ending Sep 2025
Revenue113306677
Cost of revenue33145408
Gross profit80161270
SG&A5779431,044
Operating income-497-782-774
Pretax income-526-1,048-831
Income tax112
Net income attributable to owners-527-1,050-834
Operating margin-440.0%-256.0%-114.3%

Balance sheet (reported items)

Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.

Assets

Cash 94%
6%

Funding

Other liabilities 12%
Equity 88%

Each bar totals 100% of assets; other is the residual.

ItemFY ending Sep 2023FY ending Sep 2024FY ending Sep 2025
Cash and equivalents¥1.13B¥4.39B¥2.92B
Total assets¥1.21B¥4.53B¥3.09B
Net assets¥1.15B¥3.5B¥2.71B
Share capital¥12.2M¥1.71B¥1.73B
Property, plant and equipment¥0¥0¥0
Current assets¥1.2B¥4.48B¥3.04B
Current liabilities¥63.2M¥1.02B¥370.1M
Total liabilities¥63.4M¥1.03B¥376.9M
Equity attributable to owners of parent¥1.15B¥3.5B¥2.7B
Retained earnings-¥493.2M-¥1.54B-¥2.38B

Sources

Show source documents (2)
  • EDINET (FSA Japan)

    有価証券報告書-第14期(2024/10/01-2025/09/30)

    ID S100XCIN2025-12-24Open
  • EDINET (FSA Japan)

    有価証券報告書-第13期(2023/10/01-2024/09/30)

    ID S100V11F2024-12-27Open

Extracted from XBRL: 36 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.